aminomethyl 3-furyl ketone hydrochloride | 88352-90-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: aminomethyl 3-furyl ketone hydrochloride
• 英文别名: (furan-3-ylcarbonyl)methylamine hydrochloride；(3-furylcarbonyl)methylamine hydrochloride；2-amino-1-(furan-3-yl)ethanone;hydrochloride
• CAS: 88352-90-3
• 化学式: C₆H₇NO₂*ClH
• 分子量: 161.588
• InChiKey: CHOQKBKQDVRWOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.84
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  56.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  aminomethyl 3-furyl ketone hydrochloride 在 sodium hydride 、 碳酸氢钠 作用下， 以 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 paraffin 为溶剂， 反应 0.83h， 生成 ethyl 3--4-(3-furyl)-4-oxobutyrate
  参考文献：
  名称：

  Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds

  摘要：

  A series of 2-aryl and 2-alkyl derivatives of 5-furyl-4-oxazoleacetic acid and their homologues having alkyl groups at the alpha-position of the acids were synthesized and evaluated for their hypolipidemic activities in Sprague-Dawley rats. On the basis of the structure-activity relationships and subacute toxicities, ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate (35) was selected as a candidate compound for development. Compound 35 reduced serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dose of 0.05% in a diet in normal rats, and it was about 10 times more active in hereditary hyperlipidemic rats (THLR/1) than in normal rats. Compound 35 inhibited platelet aggregation in vitro and also normalized hyperaggregability of hyperlipidemic plasma platelet ex vivo.

  DOI：

  10.1021/jm00401a021
• 作为产物：
  描述：

  methyl 5-(3-furyl)oxazole-4-carboxylate 在 盐酸 作用下， 生成 aminomethyl 3-furyl ketone hydrochloride
  参考文献：
  名称：

  Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds

  摘要：

  A series of 2-aryl and 2-alkyl derivatives of 5-furyl-4-oxazoleacetic acid and their homologues having alkyl groups at the alpha-position of the acids were synthesized and evaluated for their hypolipidemic activities in Sprague-Dawley rats. On the basis of the structure-activity relationships and subacute toxicities, ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate (35) was selected as a candidate compound for development. Compound 35 reduced serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dose of 0.05% in a diet in normal rats, and it was about 10 times more active in hereditary hyperlipidemic rats (THLR/1) than in normal rats. Compound 35 inhibited platelet aggregation in vitro and also normalized hyperaggregability of hyperlipidemic plasma platelet ex vivo.

  DOI：

  10.1021/jm00401a021

文献信息

• Furyloxazolylacetic acid derivatives and processes for preparing same
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US04642313A1

  公开（公告）日：1987-02-10

  A furyloxazolylacetic acid derivative of the formula: ##STR1## wherein R.sup.1 is alkyl of one to 6 carbon atoms, cycloalkyl of 5 to 6 carbon atoms, phenyl or a substituted phenyl (said substituted phenyl being phenyl group substituted with one or two radicals selected from alkyl of one to 2 carbon atoms, alkoxy of one to 2 carbon atoms and halogen), and R.sup.2 is hydrogen or alkyl of one to 12 carbon atoms. The compound (I) is useful as a hypolipidemic agent.

  一种 furyloxazolylacetic 酸衍生物的化学式为：##STR1## 其中 R.sup.1 是1至6个碳原子的烷基，5至6个碳原子的环烷基，苯基或取代苯基（所述取代苯基是苯基，其上取代有一个或两个来自1至2个碳原子的烷基、1至2个碳原子的烷氧基和卤素的基团），而 R.sup.2 是氢或1至12个碳原子的烷基。该化合物（I）可用作降脂药剂。
• Furyloxazolylacetic acid derivative, processes for preparing same and pharmaceutical composition
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0120270A2

  公开（公告）日：1984-10-03

  A furyloxazolylacetic acid derivative of the formula: wherein R' is lower alkyl, R2 is hydrogen atom or lower alkyl, R3 is hydrogen atom or lower alkyl and ring A is phenyl or halogenophenyl, processes for preparing same and pharmaceutical compositions containing the new compounds, which are useful as a hypolipidemic agent are disclosed.

  一种式中R'为低级烷基，R2为氢原子或低级烷基，R3为氢原子或低级烷基，环A为苯基或卤素苯基的呋喃恶唑乙酸衍生物，其制备方法以及含有该衍生物的药物组合物： 其中R'为低级烷基，R2为氢原子或低级烷基，R3为氢原子或低级烷基，环A为苯基或卤代苯基，公开了制备这些新化合物的工艺和含有这些新化合物的药物组合物，它们可用作降血脂剂。
• Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors
  作者：Suk Ho Lee、Min Ju Kim、Sung-Han Lee、Jeongmin Kim、Hyun-Ju Park、Jinhwa Lee

  DOI：10.1016/j.ejmech.2011.03.052

  日期：2011.7

  In order to investigate SAR regarding proximal phenyl ring in novel C-aryl glucoside SGLT2 inhibitors containing a thiazole motif, a series of chemical modifications on proximal phenyl ring was conducted. During a series of lead optimization efforts, ortho-allyloxyphenyl 10p or ortho-hydroxyphenyl ha showed subnanomolar inhibitory activity against hSGLT2. (C) 2011 Elsevier Masson SAS. All rights reserved.
• Tetrahydropyranyl derivatives, process for their preparation and pharmaceutical or veterinary compositions containing them
  申请人：BEECHAM GROUP PLC

  公开号：EP0399645B1

  公开（公告）日：1994-11-09
• ——
  作者：MATSUMOTO KAZUO、 TAKASHIMA KOHKI

  DOI：——

  日期：——